Sanofi and SK Bioscience Report Result of GBP410 in P-II Trial to Treat Pneumococcal Diseases in Infants
Shots:
- The P-II clinical trial evaluates the safety & immunogenicity GBP410 vs control vaccine in infants (n=140, aged 12-15mos. & n=712, aged 42-89days) across the US, Canada & Honduras
- The results depicted comparable immunogenicity of GBP410 vs control vaccine following primary vaccination at 2, 4, & 6mos. of age along with the booster vaccination at 12-15mos. Additionally, GBP410 showed a well-tolerated safety profile& did not interfere with the immunogenicity & safety profile of the co-administered recommended pediatric vaccines like tetanus, polio etc.
- A joint development of SK Bioscience & Sanofi, GBP410 is a pneumococcal conjugate vaccine that combines specific proteins with the polysaccharide capsule of Streptococcus pneumoniae which causes pneumococcal diseases like pneumonia & invasive pneumococcal disease
Ref: PR Newswire | Image: Sanofi
Related News:- GSK and SK Bioscience Initiate P-III Study of GBP510 Against AZ/Oxford's COVID-19 Vaccine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
